Last reviewed · How we verify

NCT05470166: ERAS

Lidocaine Infusion With ERAS Protocol for Pancreatic Cancer Surgery: Effect on Pain and Patient Immunity.

Completed NA Last updated 21 August 2024
What this trial tests

NA trial testing Lidocaine IV in ERAS in 30 participants. Completed in 1 April 2024.

Timeline
20 April 2022
Primary endpoint
17 January 2024
1 April 2024

Quick facts

Lead sponsorAlexandria University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposehealth services research
Enrollment30
Start date20 April 2022
Primary completion17 January 2024
Estimated completion1 April 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Alexandria University

Who can join

Adults 30 to 70, any sex, with ERAS or Lidocaine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The whole world now is directed to implement strategies that enhance the patient's quality of life and prevent tumor relapse. Enhanced recovery after pancreatic surgery (ERAPS) program was found to improve the quality of life as it is an evidence-based protocol designed to standardize and optimize perioperative medical care in order to reduce surgical trauma, perioperative physiological stress, organ dysfunction, reduction of clinical complications, length of hospital stay and the health costs together with increase of patient satisfaction. lidocaine; it is an amide local anaesthetic Recently its use as intravenous perioperative infusion for abdominal cancer surgeries is encouraging, as it significantly reduces postoperative pain, opioid consumption and nausea and vomiting. it also promotes gastrointestinal function recovery, and shortens the postoperative hospital stay. In addition, lidocaine in particular can act directly and indirectly on pancreatic cancer cells and the tumor microenvironment. The investigators suggest that IV lidocaine infusion in combination with ERAPS protocol may achieve better postoperative outcomes after pancreatic surgery for cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications.
    Pu T, Sun J, Ren G, Li H. · · 2025 · cited 34× · PMID 40456735 · DOI 10.1038/s41392-025-02241-8
  2. The neuro-immune axis in cancer: from mechanisms to therapeutic opportunities.
    Zhang C, Guo X, Liu P, Wang Y, et al · · 2025 · cited 6× · PMID 41152924 · DOI 10.1186/s13045-025-01748-5
  3. Trial watch: local anesthetics in cancer therapy.
    Carnet Le Provost K, Kepp O, Kroemer G, Bezu L. · · 2024 · cited 5× · PMID 38504848 · DOI 10.1080/2162402x.2024.2308940

Verify or expand the search:

Other trials of Lidocaine IV

Trials testing the same drug.

Other recruiting trials for ERAS

Currently open trials in the same condition.

Other Alexandria University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05470166.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing